Systemic Juvenile Idiopathic Arthritis

Also known as: Systemic Juvenile Idiopathic Arthritis (SJIA) / SJIA / Systemic onset juvenile idiopathic arthritis / Still's disease NOS / Systemic onset juvenile chronic arthritis (disorder) / Still's disease / Still's disease -RETIRED- / Juvenile-Onset Still Disease / Polyarticular juvenile rheumatoid arthritis (disorder) [Ambiguous] / Juvenile rheumatoid arthritis &/or Still's disease / Still's disease - juvenile rheumatoid arthritis (disorder)

DrugDrug NameDrug Description
DB00026AnakinraA recombinant form of human interleukin-1 receptor antagonist used in the treatment of rheumatoid arthritis, neonatal-onset multisystem inflammatory disease and deficiency of interleukin-1 receptor antagonist (DIRA).
DB06168CanakinumabAn interleukin-1β blocker used to treat Periodic Fever Syndromes such as Cryopyrin-Associated Periodic Syndromes (CAPS) and Familial Mediterranean Fever (FMF), and also to treat active Systemic Juvenile Idiopathic Arthritis (SJIA).
DB06273TocilizumabAn interleukin-6 (IL-6) receptor antagonist used to treat Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), and Rheumatoid Arthritis (RA).
DrugDrug NamePhaseStatusCount
DB06372Rilonacept1Completed1
DB00087Alemtuzumab2Recruiting1
DB01073Fludarabine2Recruiting1
DB01005Hydroxyurea2Recruiting1
DB01042Melphalan2Recruiting1
DB04572Thiotepa2Recruiting1
DB11817Baricitinib3Recruiting1
DB06168Canakinumab3Completed4
DB06168Canakinumab3Terminated1
DB06168Canakinumab3Withdrawn1
DB06273Tocilizumab3Completed3